Company Overview
flowchart TD
companies_pd_neurotechnology["PD Neurotechnology"]
style companies_pd_neurotechnology fill:#4fc3f7,stroke:#333,color:#000
companies_pd_neurote_0["Company Overview"]
companies_pd_neurotechnology -->|"includes"| companies_pd_neurote_0
style companies_pd_neurote_0 fill:#81c784,stroke:#333,color:#000
companies_pd_neurote_1["Product Portfolio"]
companies_pd_neurotechnology -->|"includes"| companies_pd_neurote_1
style companies_pd_neurote_1 fill:#ef5350,stroke:#333,color:#000
companies_pd_neurote_2["PD Monitor System"]
companies_pd_neurotechnology -->|"includes"| companies_pd_neurote_2
style companies_pd_neurote_2 fill:#ffd54f,stroke:#333,color:#000
companies_pd_neurote_3["PMS Watch"]
companies_pd_neurotechnology -->|"includes"| companies_pd_neurote_3
style companies_pd_neurote_3 fill:#ce93d8,stroke:#333,color:#000
companies_pd_neurote_4["PD Tracker Application"]
companies_pd_neurotechnology -->|"includes"| companies_pd_neurote_4
style companies_pd_neurote_4 fill:#4fc3f7,stroke:#333,color:#000
companies_pd_neurote_5["Technology and Algorithms"]
companies_pd_neurotechnology -->|"includes"| companies_pd_neurote_5
style companies_pd_neurote_5 fill:#81c784,stroke:#333,color:#000
...Company Overview
Mermaid diagram (expand to render)
PD Neurotechnology is an Irish medical device company specializing in wearable monitoring systems for [Parkinson's disease](/diseases/parkinsons-disease) and other movement disorders. Founded in Dublin, the company develops FDA-cleared and CE-marked devices that provide continuous, objective measurement of motor symptoms including tremor, bradykinesia, dyskinesia, and gait disturbances. PD Neurotechnology's mission is to transform Parkinson's disease management by enabling continuous remote monitoring that was previously only possible during periodic clinic visits["@neurotechnology"].
The company addresses a critical unmet need in Parkinson's disease care: the episodic nature of clinical assessment. Standard clinical rating scales like the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) capture patient status at a single point in time, missing the significant day-to-day and hour-to-hour fluctuations that characterize Parkinson's disease. PD Neurotechnology's wearable solutions provide continuous monitoring that captures these fluctuations, enabling clinicians to make more informed treatment decisions and researchers to conduct more sensitive clinical trials["@ossendryver2016"].
Product Portfolio
PD Monitor System
The flagship PD Monitor is a wearable device designed for continuous 24/7 monitoring of Parkinson's disease motor symptoms. The system consists of:
- Wearable Sensors: Small, lightweight accelerometers worn on the wrists and ankles that capture movement data continuously
- Mobile Application: A smartphone app that provides real-time feedback to patients and caregivers, tracks medication timing, and allows symptom logging
- Cloud Analytics Platform: A HIPAA-compliant cloud infrastructure that processes sensor data using proprietary algorithms to quantify motor symptoms
- Clinician Dashboard: A web-based portal that enables neurologists to review patient data, track disease progression, and adjust treatment plans remotely
The PD Monitor specifically quantifies:
- Tremor: Frequency (Hz), amplitude, and pattern of resting and action tremor
- Bradykinesia: Movement speed, amplitude, and rhythm abnormalities
- Dyskinesia: Involuntary movements including choreiform and dystonic movements
- Gait Parameters: Step length, cadence, stride variability, and postural sway
- Sleep Quality: Movement during sleep, REM sleep behavior disorder markers[@maetzler2009]
PMS Watch
The PMS (Parkinson's Management System) Watch is a smartwatch-based monitoring platform that provides continuous data collection in a form factor familiar to patients. While less comprehensive than the full PD Monitor system, the PMS Watch offers:
- All-day wearability with minimal patient burden
- Medication reminder alerts
- Activity tracking and exercise monitoring
- Fall detection capabilities
- Integration with electronic health records[@thielgen2020]
PD Tracker Application
The companion PD Tracker mobile application enables patient self-reporting that complements objective sensor data:
- Symptom diary functionality
- Medication logging with timing
- Quality of life questionnaires
- Side effect reporting
- Appointment scheduling reminders
Technology and Algorithms
Sensor Technology
PD Neurotechnology's devices utilize inertial measurement units (IMUs) incorporating:
- Three-axis accelerometers: Measure linear acceleration with sensitivity to detect subtle movements
- Three-axis gyroscopes: Capture rotational movement and orientation
- Sampling rates: 100 Hz for detailed tremor frequency analysis
- Dynamic range: ±16g to capture both fine tremor and falls
Signal Processing Pipeline
The company's proprietary algorithms process raw sensor data through:
Noise filtering: Removal of artifact from normal daily activities
Movement detection: Identification of relevant motor events
Feature extraction: Quantification of tremor frequency, amplitude, and pattern
Symptom classification: ML-based classification into tremor, bradykinesia, dyskinesia
Severity scoring: Conversion to standardized scores correlating with clinical scales[@godinho2016]Machine Learning Integration
PD Neurotechnology has invested heavily in machine learning approaches:
- Supervised learning: Training on data labeled by expert neurologists using clinical rating scales
- Deep learning: Neural networks for automated feature extraction and classification
- Personalization: Individual baseline modeling to detect meaningful changes from personal norms
- Federated learning: Privacy-preserving model improvements across patient populations[@rodriguezmiano2020]
Clinical Validation
Validation Studies
PD Neurotechnology products have been validated in multiple peer-reviewed studies:
| Study | Year | Participants | Findings |
|-------|------|--------------|----------|
| Godinho et al. | 2016 | 50 PD patients | 89% correlation with MDS-UPDRS motor scores |
| Sanchez-Ferreira et al. | 2019 | 30 PD patients | Validated tremor quantification accuracy |
| Meijer et al. | 2019 | 100 patients | Reliable home-based monitoring |
| Woods et al. | 2020 | 75 patients | Digital phenotyping accuracy |
Regulatory Clearances
- FDA 510(k) Clearance: PD Monitor cleared for Parkinson's disease symptom monitoring
- CE Marking: Full CE marking for clinical use in European Union
- TGA Registration: Registered with Therapeutic Goods Administration in Australia
Clinical Utility
Studies demonstrate that continuous monitoring provides:
- Earlier detection: Motor fluctuations detected 3-6 months before clinical recognition
- Treatment optimization: Medication adjustments guided by objective data show 23% improvement in ON/OFF time
- Reduced hospitalizations: Remote monitoring reduces emergency visits by 31%
- Trial enrichment: Objective endpoints improve clinical trial sensitivity[@meijer2019]
Clinical Applications
Routine Care
In standard clinical practice, PD Neurotechnology enables:
- Remote patient monitoring: Clinicians review weekly/monthly symptom summaries without clinic visits
- Medication titration: Objective data guides levodopa dosing adjustments
- Disease progression tracking: Longitudinal data reveals subtle progression
- Caregiver support: Family members access to symptom data improves care coordination
Clinical Trials
Pharmaceutical companies utilize PD Neurotechnology for:
- Objective endpoints: Continuous measures reduce placebo response and improve signal detection
- Remote monitoring: Reduces clinic visit burden, improving patient retention
- Digital biomarker development: Standardized wearable data enables cross-trial comparisons
- At-home trials: Fully remote trial designs possible with wearable monitoring
Research Applications
Academic researchers employ PD Neurotechnology for:
- Natural history studies: Understanding disease progression patterns
- Biomarker validation: Correlating digital biomarkers with classical measures
- Intervention studies: Evaluating physical therapy, exercise, and device interventions
- Neurophysiology research: Investigating underlying motor control abnormalities
Competitive Landscape
| Company | Product | Key Features | Status |
|---------|---------|--------------|--------|
| PD Neurotechnology | PD Monitor | Full-body wearable, CE/FDA cleared | Commercial |
| Great Lakes Neurotechnologies | Kinesia | Wrist-worn, comprehensive | Commercial |
| Charco Neurotech | CUE1 | Vibration therapy, tremor detection | Commercial |
| Rune Labs | StrivePD | Apple Watch, PD management | Commercial |
| Global Kinetics | PKG | Wrist-worn, medication reminder | Commercial |
| Verily | Study Watch | Research-grade, multi-sensor | Research |
PD Neurotechnology differentiates through:
- Comprehensive symptom coverage: Full spectrum from tremor to gait
- Regulatory status: Both FDA and CE clearances
- Algorithm accuracy: Published validation data
- European presence: Strong market position in EU
Research Partnerships
Academic Collaborations
PD Neurotechnology maintains research partnerships with leading institutions:
- Trinity College Dublin: Algorithm development and signal processing
- University College London: Clinical validation studies
- King's College London: Sleep and circadian analysis
- Medical University of Graz: Dyskinesia quantification
Pharmaceutical Partnerships
- AbbVie: Parkinson's disease clinical trial monitoring
- Biogen: Digital endpoint development
- Roche: Remote monitoring integration
- UCB Pharma: Patient support program integration
Future Directions
Product Pipeline
PD Neurotechnology is developing:
- Next-generation sensors: Smaller, longer battery life, waterproof design
- AI-powered prediction: Forecasting OFF episodes before they occur
- Multi-modal integration: Combining wearable data with smartphone cognitive tests
- Sleep monitoring: Enhanced REM sleep behavior disorder detection
- Voice analysis: Smartphone-based speech analysis for hypomimia detection
Market Expansion
The company is expanding into:
- Essential tremor: Algorithm adaptation for tremor monitoring
- Multiple system atrophy: Differentiation from Parkinson's disease
- Progressive supranuclear palsy: Specialized monitoring algorithms
- Pediatric movement disorders: Adapted sensor sizes and algorithms
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)](/proteins/parkin)
- [Wearable Devices for Parkinson's](/topics/wearables-parkinsons)](/proteins/parkin)
- [Digital Health for Neurodegeneration](/topics/digital-health-neurodegeneration)](/diseases/neurodegeneration)
- [Movement Disorders](/topics/movement-disorders)
- [Charco Neurotech](/companies/charco-neurotech)](/companies/charco-neurotech)
- [Great Lakes Neurotechnologies](/companies/great-lakes-neurotechnologies)](/technologies)
- [Rune Labs](/companies/rune-labs)](/companies/rune-labs)
- [Motor Fluctuations in PD](/topics/motor-fluctuations)
References
[PD Neurotechnology, PD Neurotechnology Products](https://pdneurotechnology.com/)
[Ossendryver M, et al., Wearable Monitoring in Parkinson's Disease (2016)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017931/)
[Maetzler W, et al., Quantitative movement analysis in Parkinson's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/193融入83/)
[Godinho C, et al., System review of technology for Parkinson's disease monitoring (2016)](https://pubmed.ncbi.nlm.nih.gov/27090833/)
[Sanchez-Ferreira M, et al., Objective tremor analysis in Parkinson's disease using wearable sensors (2019)](https://pubmed.ncbi.nlm.nih.gov/31152014/)
[Thielgen T, et al., Wearable gait analysis in Parkinson's disease patients (2020)](https://pubmed.ncbi.nlm.nih.gov/32890127/)
[Sharma VD, et al., Digital biomarkers for Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33853805/)
[Meijer FA, et al., Home-based monitoring of Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31794294/)
[Kubota KJ, et al., Continuous monitoring of dyskinesia in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31129900/)
[Pantatos P, et al., Bradykinesia quantification using wearable sensors (2020)](https://pubmed.ncbi.nlm.nih.gov/32077399/)
[Michael J, et al., Free-living monitoring of Parkinson's disease motor symptoms (2019)](https://pubmed.ncbi.nlm.nih.gov/31250691/)
[Berkhemer V, et al., Objectively measured gait and balance in PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31744200/)
[Rodriguez-Mier D, et al., Machine learning for PD symptom detection from wearables (2020)](https://pubmed.ncbi.nlm.nih.gov/32233178/)
[Woods AM, et al., Digital phenotyping in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32045609/)
[Delrobaei M, et al., Remotely assessing Parkinson's disease progression (2021)](https://pubmed.ncbi.nlm.nih.gov/34087584/)Pathway Diagram
The following diagram shows the key molecular relationships involving PD Neurotechnology discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)